H.R. 6625 · 117th Congress · House

Equal Access to Therapeutics Act

Active· Referred to the Subcommittee on Health.
Introduced
Feb 7, 22
Passed House
Pending
Passed Senate
Pending
Sent to President
Pending
Signed into Law
Pending

Executive Summary

Equal Access to Therapeutics Act

This bill prohibits using race or ethnicity as a factor in decisions about an individual's access to COVID-19 treatments (e.g., monoclonal antibody therapies).

Specifically, the Department of Health and Human Services (HHS) may not adopt any policy or guidance that allows race or ethnicity to be factored into such decisions. Furthermore, the Secretary of HHS shall be personally liable for the death of any individual who is denied access to COVID-19 treatments pursuant to a prohibited policy or guidance.

The bill also prohibits hospitals or other health care providers that have policies restricting access to COVID-19 treatments based on race or ethnicity from receiving federal funds.

Action Timeline

4
  1. FEB 08, 2022Committee

    Referred to the Subcommittee on Health.

  2. FEB 07, 2022IntroReferral

    Introduced in House

  3. FEB 07, 2022IntroReferral

    Introduced in House

  4. FEB 07, 2022IntroReferral

    Referred to the House Committee on Energy and Commerce.

Committees

2

Health Subcommittee

hsif14

Referred: Feb 8, 2022

Active

Energy and Commerce Committee

hsif00

Referred: Feb 7, 2022

Active